CTOR
Citius Oncology, Inc.Company with tickers: CTOR
CIK
1851484
CUSIP
17331Y109
Shares Outstanding
92,981,204
Website
https://www.citiusonc.com
13F Activity (30d)
4 filings
4 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,667,298 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | $328,878 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Gross Profit | $1,338,420 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Expenses | $29,952,015 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $1,079,354 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-28,613,595 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-26,609,695 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.27 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.27 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |